PMID- 38287840
OWN - NLM
STAT- MEDLINE
DCOM- 20240131
LR  - 20240206
IS  - 0219-6352 (Print)
IS  - 0219-6352 (Linking)
VI  - 23
IP  - 1
DP  - 2024 Jan 10
TI  - Association between MTHFR C677T Gene Polymorphisms and the Efficacy of Vitamin 
      Therapy in lowering Homocysteine Levels among Stroke Patients with 
      Hyperhomocysteinemia.
PG  - 3
LID - 10.31083/j.jin2301003 [doi]
AB  - BACKGROUND: The impact of the methylenetetrahydrofolate reductase (MTHFR) C677T 
      mutation on the relationship between plasma homocysteine (Hcy) levels and stroke 
      has been extensively studied and documented in previous study. However, it 
      remains unclear whether the MTHFR C677T mutation can affect the response to Hcy 
      lowering treatment in stroke patients with hyperhomocysteinemia (HHcy). 
      Understanding the impact of genetic factors on treatment response can help 
      optimize personalized treatment strategies for stroke patients with HHcy. We 
      aimed to investigate the potential association between the MTHFR C677T gene 
      polymorphisms and the effectiveness of Hcy lowering treatment using vitamin 
      therapy in stroke patients with HHcy. METHODS: The MTHFR C677T genotype 
      polymorphisms were identified using polymerase chain reaction-restriction 
      fragment length polymorphism, and the distribution of three genotypes in the 
      MTHFR C677T gene locus was compared. The treatment effects of Hcy lowering agents 
      were compared among patients with different genotypes. RESULTS: Among the 320 
      stroke patients enrolled in the study, 258 (80.6%) were diagnosed with HHcy. Of 
      these, 162 patients (Effective Group) responded well to the clinical Hcy lowering 
      treatment, while 96 patients (Invalid Group) failed to achieve sufficient 
      response even after taking combination supplements of folic acid, Vitamin B6, and 
      methylcobalamin for one month. Significant differences were observed in terms of 
      age (p < 0.001), hypertension (p = 0.034), dyslipidemia (p = 0.022), 
      hyperuricemia (p = 0.013) and genotype distribution of MTHFR C677T gene 
      polymorphism (p < 0.001) between the Invalid group and the Effective group. The 
      multivariate regression analysis revealed that the T allele (odd rations [OR], 
      1.327; 95% confidence interval [CI], 1.114-1.580; p = 0.0015) was independently 
      associated with an insufficient Hcy lowering treatment effect. Additionally, the 
      TT genotype was independently associated with insufficient response in both the 
      codominant model (OR, 1.645; 95% CI, 1.093-2.476; p = 0.017) and the recessive 
      model (TT versus CC + CT; OR, 1.529; 95% CI, 1.145-2.042; p = 0.004). However, no 
      relationship was observed between CT + TT genotypes and poor treatment effect in 
      the dominate model. CONCLUSIONS: Our findings suggested that the TT genotype and 
      T allele of MTHFR C677T polymorphism were independently associated with an 
      insufficient Hcy lowering treatment effect in stroke patients with HHcy.
CI  - (c) 2024 The Author(s). Published by IMR Press.
FAU - Li, Zhi-Can
AU  - Li ZC
AD  - Department of Neurology, Quanzhou First Hospital Affiliated to Fujian Medical 
      University, 362000 Quanzhou, Fujian, China.
FAU - Huang, Min
AU  - Huang M
AD  - Department of Geriatrics, The 900th Hospital of Joint Logistics Support Force of 
      Chinese PLA, 350025 Fuzhou, Fujian, China.
FAU - Yao, Qing-Yang
AU  - Yao QY
AD  - Department of Neurology, Quanzhou First Hospital Affiliated to Fujian Medical 
      University, 362000 Quanzhou, Fujian, China.
FAU - Lin, Cai-Hong
AU  - Lin CH
AD  - Department of Neurology, Quanzhou First Hospital Affiliated to Fujian Medical 
      University, 362000 Quanzhou, Fujian, China.
FAU - Hong, Bing-Cong
AU  - Hong BC
AD  - Department of Neurology, Quanzhou First Hospital Affiliated to Fujian Medical 
      University, 362000 Quanzhou, Fujian, China.
FAU - Wang, Jie-Hua
AU  - Wang JH
AD  - Department of Neurology, Quanzhou First Hospital Affiliated to Fujian Medical 
      University, 362000 Quanzhou, Fujian, China.
FAU - Zhang, Zedan
AU  - Zhang Z
AD  - Department of Health Medicine, The 900th Hospital of Joint Logistics Support 
      Force of Chinese PLA, 350025 Fuzhou, Fujian, China.
LA  - eng
PT  - Journal Article
PL  - Singapore
TA  - J Integr Neurosci
JT  - Journal of integrative neuroscience
JID - 101156357
RN  - EC 1.5.1.20 (Methylenetetrahydrofolate Reductase (NADPH2))
RN  - 0LVT1QZ0BA (Homocysteine)
RN  - 0 (Vitamins)
RN  - EC 1.5.1.20 (MTHFR protein, human)
SB  - IM
MH  - Humans
MH  - *Hyperhomocysteinemia/drug therapy/genetics
MH  - Polymorphism, Genetic
MH  - *Stroke/complications/drug therapy/genetics
MH  - Methylenetetrahydrofolate Reductase (NADPH2)/genetics
MH  - Homocysteine/genetics
MH  - Vitamins
OTO - NOTNLM
OT  - homocysteine
OT  - methylenetetrahydrofolate reductase
OT  - single nucleotide polymorphism
OT  - stroke
COIS- The authors declare no conflict of interest.
EDAT- 2024/01/30 06:42
MHDA- 2024/01/31 06:42
CRDT- 2024/01/30 02:53
PHST- 2023/03/21 00:00 [received]
PHST- 2023/04/26 00:00 [revised]
PHST- 2023/05/10 00:00 [accepted]
PHST- 2024/01/31 06:42 [medline]
PHST- 2024/01/30 06:42 [pubmed]
PHST- 2024/01/30 02:53 [entrez]
AID - S0219-6352(23)00562-4 [pii]
AID - 10.31083/j.jin2301003 [doi]
PST - ppublish
SO  - J Integr Neurosci. 2024 Jan 10;23(1):3. doi: 10.31083/j.jin2301003.